medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2024, Number S1

<< Back

Rev Latin Infect Pediatr 2024; 37 (S1)

Consensus of the Mexican Association of Paediatric Infectious Diseases (AMIP): childhood vaccination against COVID-19 in Mexico, 2024

Otero MFJ, Ortiz IFJ, Avilés RM, Camacho MG, Díaz JV, Espinosa SMC, Luévanos VA, Mascareñas SA, Merlo PM, Ortiz CB, Reyes BM, Rincón ZJ, Rodríguez ML, Vaquera AD, González SN

Language: Spanish
References: 35
Page: s50-64
PDF size: 420.88 Kb.


ABSTRACT

Introduction: the COVID-19 pandemic has posed the most significant health challenge of the 21st century. The development of new vaccines has been the most effective defense against this biological threat. However, the pediatric population may currently be the most vulnerable group, primarily due to lower vaccine coverage. Material and methods: utilizing an academic consensus model, we compiled and critically reviewed the available scientific literature on current and controversial topics related to COVID-19 in pediatrics. We followed the guidelines outlined in the "Guidelines for the Development of Consensus" and the European AGREE initiative, emphasizing critical reading and evaluation criteria. The recommendations are presented using the GRADE scale. The consensus involved multidisciplinary teams comprising pediatricians and pediatric infectious disease specialists affiliated with Mexican Association of Pediatric Infectology (AMIP). The studies and manuscripts reviewed were selected based on keywords such as "pediatrics COVID-19", "vaccine", "epidemiology", "vaccine safety and efficacy", and "vaccine compliance", using databases like PubMed, Google Scholar, EMBASE, Cochrane, and virtual libraries from Oxford, Harvard, and Tecnológico de Monterrey. Priority was given to articles published between January 2019 and August 2024, with older references included for context or when they represented the most robust information available. The consensus process involved one in-person meeting, two virtual sessions, and external review by two independent experts. Results: ten relevant and/or controversial topics were identified and subjected to academic analysis based on the evidence found in the included literature. The results of the critical review of the selected articles were presented with their corresponding GRADE recommendation level.


REFERENCES

  1. Ferrario DC, Califano DG, Durán P et al. Lineamientos para la elaboración de Consensos Guidelines for planning consensus Sociedad Argentina de Pediatría Subcomisiones, Comités y Grupos de Trabajo. Arch Argent Pediatr. 110 (2): 163-167. https://doi.org/10.5546/aap.2012.163

  2. AGREE Trust. (n.d.). The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. Available in: https://Www.Agreetrust.Org/Resource-Centre/the-Originalagree-Instrument/

  3. Guyatt G, Oxman AD, Akl EA et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology. 2011; 64 (4): 383-394. Available in: https://doi.org/10.1016/J.JCLINEPI.2010.04.026

  4. Manterola C, Asenjo-Lobos C, Otzen T. Jerarquización de la evidencia: Niveles de evidencia y grados de recomendación de uso actual. Revista Chilena de Infectología. 2014; 31 (6): 705-718. Disponible en: https://doi.org/10.4067/S0716-10182014000600011

  5. WHO COVID-19 dashboard. Available in: https://data.who.int/dashboards/covid19/cases?n=o

  6. SINAVE/DGE/Vigilancia Epidemiológica de Enfermedad Respiratoria Viral, acceso al 22/07/2024.

  7. WHO. Tracking SARS-CoV-2 variants Available in: https://www.who.int/es/activities/tracking-SARS-CoV2-variants

  8. Organización Mundial de la Salud. WHO clinical case definition of post COVID-19 condition (2023). Organización Mundial de la Salud; 2023 [citado 2024 Jul 19]. Available in: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-CA-Clinical-case-definition-2023-1

  9. Li J, Zhou Y, Ma J et al. The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID. Sig Transduct Target Ther. 2023; 8: 416. Available in: https://doi.org/10.1038/s41392-023-01640-z

  10. Clinical Overview of Long COVID. Available in: https://www.cdc.gov/covid/hcp/clinical-overview/index.html

  11. Henderson LA, Canna SW, Friedman KG et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol. 2022; 74 (4): e1-e20. doi: 10.1002/art.42062.

  12. Kompaniyets L, Bull-Otterson L, Boehmer TK et al. Post-COVID-19 Symptoms and Conditions Among Children and Adolescents - United States, March 1, 2020-January 31, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71 (31): 993-999. doi: 10.15585/mmwr.mm7131a3.

  13. Hause AM, Baggs J, Marquez P et al. COVID-19 vaccine safety in children aged 5-11 years - United States, November 3-December 19, 2021. MMWR. Morbidity and mortality weekly report. 2021; 70: 5152, 1755-1760. Available in: https://doi.org/10.15585/mmwr.mm705152a1

  14. Guo BQ, Li HB, Yang LQ. Incidence of myopericarditis after mRNA COVID-19 vaccination: a meta-analysis with focus on adolescents aged 12-17 years. Vaccine. 2023; 41 (28): 4067-4080. Available in: https://doi.org/10.1016/j.vaccine.2023.05.049

  15. Creech CB, Anderson E, Berthaud V et al. Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age. N Engl J Med. 2022; 386 (21): 2011-2023. Available in: https://doi.org/10.1056/NEJMoa2203315

  16. Lan Z, Yan J, Yang Y et al. Effectiveness of COVID-19 vaccines among children and adolescents against SARS-CoV-2 variants: a meta-analysis. Eur J Pediatr. 2023; 182: 5235-5244. Available in: https://doi.org/10.1007/s00431-023-05216-5

  17. Anderson EJ, Creech CB, Berthaud V et al. Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age. N Engl J Med. 2022; 387 (18): 1673-1687. Available in: https://doi.org/10.1056/NEJMoa2209367

  18. Gao P, Kang LY, Liu J, Liu M. Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2-18 years: an updated systematic review and meta-analysis. World J Pediatr. 2023; 19 (11): 1041-1054. Available in: https://doi.org/10.1007/s12519-022-00680-9

  19. Razzaghi H, Forrest CB, Hirabayashi K et al. Vaccine effectiveness against long COVID in children: a report from the RECOVER EHR Cohort. medRxiv [Preprint]. 2023 Sep 28:2023.09.27.23296100. Available in: https://doi.org/10.1101/2023.09.27.23296100

  20. Hause AM, Gee J, Baggs J et al. COVID-19 vaccine safety in adolescents aged 12-17 years - United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 (31): 1053-1058. doi: http://dx.doi.org/10.15585/mmwr.mm7031e1.

  21. Walter EB, Talaat KR, Sabharwal C et al. Evaluation of BNT162b2 Covid-19 Guía sobre vacunación para COVID en niños. Sociedad Latinoamericana de Infectología Pediátrica. 2023

  22. Pediatric COVID-19 Vaccine Dosing Quick Reference Guide. Academia Americana de Pediatría 2023. aap.org/CovidVaccineGuide

  23. CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus Season. Available in: http://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html

  24. Vaccines for moderately to severely immunocompromised people. CDC. [Date of consultation:28 August 2024]. Available in: Covid19.https://www.cdc.gov/covid/vaccines/immunocompromised-people.html

  25. Interim clinical considerations for use of COVID-19 vaccines in the United States. (last update: August 23, 2024). [Consultation date: August 28, 2024] Available in: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html

  26. Rasmussen SA, Kelley CF, Horton JP, Jamieson DJ. Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know. Obstet Gynecol. 2021; 137 (3): 408-414. doi: 10.1097/AOG.0000000000004290. Erratum in: Obstet Gynecol. 2021; 137 (5): 962. doi: 10.1097/AOG.0000000000004379.

  27. Ding C, Liu Y, Pang W, Zhang D, Wang K, Chen Y. Associations of COVID-19 vaccination during pregnancy with adverse neonatal and maternal outcomes: A systematic review and meta-analysis. Front Public Health. 2023; 11: 1044031. doi: 10.3389/fpubh.2023.1044031.

  28. Zambrano LD, Newhams MM, Olson SM et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years-United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022; 71 (2): 52-58.

  29. Zambrano LD, Newhams MM, Olson SM et al. BNT162b2 mRNA vaccination against coronavirus disease 2019 is associated with a decreased likelihood of multisystem inflammatory syndrome in children aged 5-18 Years-United States, July 2021-April 2022. Clin Infect Dis. 2023; 76 (3): e90-e100.

  30. Hamad Saied M, van der Griend L, van Straalen JW, Wulffraat NM, Vastert S, Jansen MHA. The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis. Pediatr Rheumatol Online J. 2023; 21 (1): 80. doi: 10.1186/s12969-023-00848-1.

  31. Simmons AE, Amoako A, Grima AA et al. Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: A retrospective cohort study. PLoS One. 2023; 18 (3): e0283715. doi: 10.1371/journal.pone.0283715.

  32. Rosa DJS, Leung D, Yip KM, Lee DHL, So HK, Wong WHS, Lau YL. COVID-19 vaccines versus pediatric hospitalization. Cell Rep Med. 2023; 4 (2): 100936. doi: 10.1016/j.xcrm.2023.100936..

  33. WHO Declaración sobre la composición antigénica de las vacunas contra la COVID-19. [Fecha consulta: 6 julio 2024] Disponible en: https://www.who.int/es/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines

  34. Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024. [Consultation date: July 6, 2024] Available in: https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2024

  35. FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. [Accessed on: August 28, 2024] Available in: https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently




2020     |     www.medigraphic.com